Epilepsy, Seizure Disorders, and Medical Cannabis in Texas

Texas patients with epilepsy or another diagnosed seizure disorder have a legal path to a low-THC cannabis prescription. That does not make all cannabis products seizure treatments. A useful decision starts with the exact seizure diagnosis, the current antiseizure regimen, the formulation under consideration, and a plan for measuring both seizures and adverse effects.

Epilepsy and Seizure Disorders Qualify in Texas

The Texas Department of Public Safety lists both epilepsy and a seizure disorder as qualifying conditions for permanent Texas residents.¹ The final enrolled law names them separately and requires the registered physician to decide whether the risk of medical use is reasonable in light of the potential benefit for that patient.² Approval is not guaranteed.

There is no state patient application to complete and no state patient registration fee. The physician confirms eligibility and enters an approved prescription in the Compassionate Use Registry of Texas. A patient under 18 may require a legal guardian, according to DPS.¹

Where the Evidence Is Strongest

The clearest evidence is not for cannabis flower, an over-the-counter CBD bottle, or every low-THC formulation. It concerns a standardized, highly purified oral cannabidiol medicine used as an add-on to existing antiseizure treatment in particular drug-resistant epilepsy syndromes.

The FDA has approved Epidiolex, a purified cannabidiol oral solution, for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year of age and older.³ FDA approval applies to that medicine, those indications, and its controlled manufacturing and labeling. It does not establish that retail CBD, Texas dispensary products, THC-containing products, or cannabis generally are safe and effective for all epilepsy.

A 2025 systematic review of seven randomized trials found that 10 and 20 mg/kg/day of cannabidiol probably increased the proportion of people who achieved at least a 50 percent reduction in monthly seizures. The same review found that serious adverse events were probably increased at 20 mg/kg/day, while the certainty for several other cannabinoid comparisons was low or very low.⁵ A separate 2025 review in children with developmental and epileptic encephalopathies described promising seizure reductions but also frequent adverse effects and limited information about long-term development and quality of life.⁶

Why Product and Dose Differences Matter

Seizure treatment depends on reliable dosing. Prescription cannabidiol has a defined concentration, manufacturing controls, dosing instructions, interaction data, and laboratory monitoring. A dispensary formulation may differ in CBD concentration, THC exposure, other cannabinoids, ingredients, and route of administration. An over-the-counter product adds another layer of uncertainty because label accuracy and contamination control can vary.

The National Center for Complementary and Integrative Health warns that CBD can cause reduced alertness, mood changes, decreased appetite, diarrhea, and liver injury, and can interact with other medicines. It also notes that nonprescription products may contain different amounts of CBD than their labels claim.⁷ These concerns are especially important when the treatment goal requires a stable blood level or when a patient takes several antiseizure medicines.

THC Is Not Interchangeable With CBD

CBD and THC are different cannabinoids. The trials supporting purified CBD do not establish that a THC-dominant product prevents seizures. THC can impair attention, coordination, judgment, and short-term memory. For some patients, intoxication, missed doses, sleep disruption, vomiting, or an inconsistent product could complicate seizure management even if the product is legally available.

Medication Interactions and Monitoring

The FDA prescribing information for Epidiolex calls for liver testing before treatment and during therapy. It warns about liver injury, sedation, suicidal thoughts or behavior, hypersensitivity, and the danger of abruptly withdrawing antiseizure treatment. Valproate and clobazam are among the medicines that require particular attention because of liver and sedation risks or drug interactions.⁴

A patient should not stop or reduce an established antiseizure medicine simply because CBD or low-THC cannabis is added. Abrupt withdrawal can increase seizure frequency and the risk of status epilepticus. The neurologist, registered CURT physician, pharmacist, patient, and caregiver should know the complete medication and supplement list and agree on who will monitor it.

• Record seizure type, frequency, duration, rescue-medication use, and injuries before changing treatment.
• Confirm the exact cannabinoid concentration, dose, route, and batch rather than relying on a product category.
• Review clobazam, valproate, other antiseizure medicines, sedatives, alcohol, and supplements for interactions.
• Ask whether baseline and follow-up liver tests are appropriate.
• Set a review date and a stopping rule if seizures, alertness, behavior, appetite, or laboratory results worsen.
• Keep the existing seizure action plan and rescue medicine available as directed.

Questions to Bring to the Neurology and CURT Visits

• What is the exact epilepsy syndrome or seizure diagnosis, and does purified CBD evidence apply to it?
• Is the proposed product comparable to the formulation studied, or is the evidence indirect?
• What CBD and THC exposure will the patient receive each day?
• Could the product change clobazam, valproate, or another medicine level or adverse-effect risk?
• What counts as meaningful improvement: fewer seizures, shorter seizures, less rescue medication, or better recovery?
• Which symptoms or laboratory changes require a call, dose adjustment, or urgent care?
• Who coordinates the plan if the neurologist and CURT physician are different clinicians?

How the Texas Prescription Process Works

Start with the official CURT physician search and, when possible, involve the clinician managing the seizure disorder.⁸ A registered physician confirms Texas residency and the diagnosis, reviews risks and potential benefits, and decides whether to prescribe. A qualifying diagnosis does not guarantee approval.

If approved, the physician enters the prescription in CURT. The patient or legal guardian then works with a licensed Texas dispensing organization. Review the full Texas qualifying conditions, the patient preparation and pickup guide, and the cannabis medication interaction checklist before the visit.